217 related articles for article (PubMed ID: 36890041)
1. ncRNA-mediated fatty acid metabolism reprogramming in HCC.
Xu K; Xia P; Chen X; Ma W; Yuan Y
Trends Endocrinol Metab; 2023 May; 34(5):278-291. PubMed ID: 36890041
[TBL] [Abstract][Full Text] [Related]
2. The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.
Liao W; Du J; Wang Z; Feng Q; Liao M; Liu H; Yuan K; Zeng Y
Int J Cancer; 2022 Aug; 151(3):337-347. PubMed ID: 35460073
[TBL] [Abstract][Full Text] [Related]
3. Noncoding RNA as therapeutic targets for hepatocellular carcinoma.
George J; Patel T
Semin Liver Dis; 2015 Feb; 35(1):63-74. PubMed ID: 25632936
[TBL] [Abstract][Full Text] [Related]
4. [Research progress of non-coding RNA involved in glycolysis regulation of hepatocellular carcinoma].
Hu XF; Zhang Q; Liang ML; Zhou QN; Zhao RQ; Gong ZK; Lin WZ
Sheng Li Xue Bao; 2024 Apr; 76(2):319-328. PubMed ID: 38658380
[TBL] [Abstract][Full Text] [Related]
5. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy.
Hou W; Bonkovsky HL
World J Gastroenterol; 2013 Nov; 19(44):7836-45. PubMed ID: 24307777
[TBL] [Abstract][Full Text] [Related]
6. Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects.
Shang RZ; Qu SB; Wang DS
World J Gastroenterol; 2016 Dec; 22(45):9933-9943. PubMed ID: 28018100
[TBL] [Abstract][Full Text] [Related]
7. Noncoding RNAs (ncRNA) in Hepato Cancer: A Review.
Sun X; Malhotra A
J Environ Pathol Toxicol Oncol; 2018; 37(1):15-25. PubMed ID: 29772997
[TBL] [Abstract][Full Text] [Related]
8. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC.
Rusu I; Pirlog R; Chiroi P; Nutu A; Puia VR; Fetti AC; Rusu DR; Berindan-Neagoe I; Al Hajjar N
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293225
[TBL] [Abstract][Full Text] [Related]
9. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review.
Hu B; Lin JZ; Yang XB; Sang XT
Cell Prolif; 2020 Mar; 53(3):e12772. PubMed ID: 32003505
[TBL] [Abstract][Full Text] [Related]
10. The Mechanism Underlying the ncRNA Dysregulation Pattern in Hepatocellular Carcinoma and Its Tumor Microenvironment.
Xue C; Gu X; Bao Z; Su Y; Lu J; Li L
Front Immunol; 2022; 13():847728. PubMed ID: 35281015
[TBL] [Abstract][Full Text] [Related]
11. Noncoding RNAs Serve as Diagnosis and Prognosis Biomarkers for Hepatocellular Carcinoma.
Tan C; Cao J; Chen L; Xi X; Wang S; Zhu Y; Yang L; Ma L; Wang D; Yin J; Zhang T; John Lu Z
Clin Chem; 2019 Jul; 65(7):905-915. PubMed ID: 30996051
[TBL] [Abstract][Full Text] [Related]
12. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways.
Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of circular RNAs, transforming growth factor-β, and long noncoding RNAs in hepatocellular carcinoma.
Shang W; Adzika GK; Li Y; Huang Q; Ding N; Chinembiri B; Rashid MS; Machuki JO
Cancer Med; 2019 Nov; 8(15):6684-6699. PubMed ID: 31523930
[TBL] [Abstract][Full Text] [Related]
14. Non-coding RNAs in hepatocellular carcinoma: Insights into regulatory mechanisms, clinical significance, and therapeutic potential.
Han Q; Wang M; Dong X; Wei F; Luo Y; Sun X
Front Immunol; 2022; 13():985815. PubMed ID: 36300115
[TBL] [Abstract][Full Text] [Related]
15. Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma.
Heo MJ; Yun J; Kim SG
Arch Pharm Res; 2019 Jan; 42(1):48-62. PubMed ID: 30610616
[TBL] [Abstract][Full Text] [Related]
16. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
17. Non-coding RNA methylation modifications in hepatocellular carcinoma: interactions and potential implications.
Shi Q; Chu Q; Zeng Y; Yuan X; Wang J; Zhang Y; Xue C; Li L
Cell Commun Signal; 2023 Dec; 21(1):359. PubMed ID: 38111040
[TBL] [Abstract][Full Text] [Related]
18. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
[TBL] [Abstract][Full Text] [Related]
19. [CLINICAL SIGNIFICANCE OF NONCODING RNA IN HEPATOCELLULAR CARCINOMA].
Eguchi H; Doki Y; Mori M
Nihon Geka Gakkai Zasshi; 2015 Nov; 116(6):366-9. PubMed ID: 26845888
[TBL] [Abstract][Full Text] [Related]
20. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.
Wong CM; Tsang FH; Ng IO
Nat Rev Gastroenterol Hepatol; 2018 Mar; 15(3):137-151. PubMed ID: 29317776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
